82 related articles for article (PubMed ID: 1435903)
1. No price too high?
Garber AM
N Engl J Med; 1992 Dec; 327(23):1676-8. PubMed ID: 1435903
[No Abstract] [Full Text] [Related]
2. Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.
Wall St J (East Ed); 2005 Nov; ():A1, A15. PubMed ID: 16502532
[No Abstract] [Full Text] [Related]
3. Why Genzyme can charge so much for Cerezyme.
Anand G
Wall St J (East Ed); 2005 Nov; ():A15. PubMed ID: 16502533
[No Abstract] [Full Text] [Related]
4. Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.
Goldman DP; Clarke AE; Garber AM
Int J Technol Assess Health Care; 1992; 8(4):583-97. PubMed ID: 1464480
[TBL] [Abstract][Full Text] [Related]
5. Low-dose versus high-frequency regimens in Gaucher's disease.
Maródi L
Lancet; 1995 Nov; 346(8987):1434. PubMed ID: 7475855
[No Abstract] [Full Text] [Related]
6. Drug development. Orphan drug windfalls?
Gershon D
Nature; 1992 Jan; 355(6359):381. PubMed ID: 1734267
[No Abstract] [Full Text] [Related]
7. [Financing of enzyme treatment in Gaucher disease].
Wisløff F
Tidsskr Nor Laegeforen; 2003 Feb; 123(3):364. PubMed ID: 12640908
[No Abstract] [Full Text] [Related]
8. [Cost reduction in the treatment of Gaucher s disease].
García Salom P; Acedo A
Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761
[No Abstract] [Full Text] [Related]
9. [Gaucher disease with multiple bone necrosis treated by enzyme replacement therapy and pamidronate].
Abe M; Minoguchi M; Jinbo J; Kikuchi Y; Chiba A; Shibata Y; Kogo Y
Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2421-3. PubMed ID: 15624481
[No Abstract] [Full Text] [Related]
10. [Gaucher disease].
Iversen PO; Wisløff F
Tidsskr Nor Laegeforen; 2003 Feb; 123(3):304-7. PubMed ID: 12640894
[No Abstract] [Full Text] [Related]
11. Economic malpractice in the treatment of Gaucher's disease.
Beutler E
Am J Med; 1994 Jul; 97(1):1-2. PubMed ID: 8030649
[No Abstract] [Full Text] [Related]
12. Initiation treatment with imiglucerase every 3 weeks in type 1 Gaucher disease.
Serratrice C; Swiader L; Serratrice J; Weiller PJ; Verrot D
Eur J Intern Med; 2012 Mar; 23(2):e71-2. PubMed ID: 22284262
[No Abstract] [Full Text] [Related]
13. Treatment of Gaucher's disease.
Barton NW; Brady RO; Dambrosia JM
N Engl J Med; 1993 May; 328(21):1564-5; author reply 1567-8. PubMed ID: 8479496
[No Abstract] [Full Text] [Related]
14. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.
Clarke JT; Amato D; Deber RB
CMAJ; 2001 Sep; 165(5):595-6. PubMed ID: 11563212
[No Abstract] [Full Text] [Related]
15. [Enzyme therapy of Gaucher's disease].
Beck M
Dtsch Med Wochenschr; 1993 Jun; 118(25):964-5. PubMed ID: 8519225
[No Abstract] [Full Text] [Related]
16. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
17. Enzyme replacement therapy in type 1 and type 3 Gaucher's disease.
Zimran A; Elstein D; Abrahamov A
Lancet; 1995 Feb; 345(8947):451-2. PubMed ID: 7853968
[No Abstract] [Full Text] [Related]
18. Low-dose versus high-frequency regimens in Gaucher's disease.
Hollak CE; Goudsmit R; van Oers MH
Lancet; 1996 Feb; 347(8998):406-7. PubMed ID: 8598739
[No Abstract] [Full Text] [Related]
19. In brief: Velaglucerase (Vpriv) for Gaucher's disease.
Med Lett Drugs Ther; 2010 May; 52(1337):36. PubMed ID: 20431522
[No Abstract] [Full Text] [Related]
20. A less costly regimen of alglucerase to treat Gaucher's disease.
Figueroa ML; Rosenbloom BE; Kay AC; Garver P; Thurston DW; Koziol JA; Gelbart T; Beutler E
N Engl J Med; 1992 Dec; 327(23):1632-6. PubMed ID: 1435900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
